There were 875 press releases posted in the last 24 hours and 357,814 in the last 365 days.

Contact

Please use this form to send email to PR contact of this press release:
Helsinn Group and MEI Pharma Discontinue the Phase 3 Study with Pracinostat in AML after Completing Interim Analysis

TO:



FROM:

Please check your email address!

Please, do not fill this field.

Please, do not change this field.

Please, do not fill if your javascript is turned off.

captcha image